The 2-year benefit of bevacizumab in colorectal cancer may explain why survival benefits are seen in studies with two-year, ...

Treosulfan plus fludarabine was approved by the FDA for children and adults with AML or MDS before allogenic hematopoietic ...

Findings from this survey also demonstrated that 23% of providers were comfortable with interpreting biomarker testing ...

Aspirin reduced disease recurrence in patients PI3K-mutated colorectal cancer, underscoring the value of early genomic ...

The phase 3 RATIONALE-306 study found no significant difference in overall survival benefits from tislelizumab plus ...

Significant improvements in skin toxicity were observed by week 6 in all patients treated with HT-001 in the phase 2a ...

Nivolumab plus chemotherapy improved long-term survival in Chinese patients with advanced gastric, GEJ, or esophageal cancer.

Five-year data shows lasting benefit for patients with advanced gastroesophageal cancers treated with nivolumab and chemotherapy.

Patients receiving ponsegromab experienced significantly greater weight gain and physical activity than those receiving placebo. Ponsegromab (PF-06946860), a GDF-15 inhibitor, increased weight gain ...

Long-Term Survival Benefit Seen With Nivolumab Plus Chemo in Chinese Patients With Advanced Gastric, GEJ, or Esophageal Cancer ...

Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers ...

Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers ...